Icon Plc (NASDAQ:ICLR) – Stock analysts at Jefferies Group cut their Q4 2017 earnings per share estimates for Icon in a research report issued to clients and investors on Tuesday, Zacks Investment Research reports. Jefferies Group analyst D. Windley now anticipates that the medical research company will post earnings per share of $1.41 for the quarter, down from their previous estimate of $1.42. Jefferies Group currently has a “Buy” rating and a $132.00 price target on the stock. Jefferies Group also issued estimates for Icon’s Q1 2018 earnings at $1.40 EPS, Q2 2018 earnings at $1.47 EPS, Q3 2018 earnings at $1.57 EPS, Q4 2018 earnings at $1.64 EPS, FY2018 earnings at $6.07 EPS and FY2019 earnings at $6.72 EPS.
Several other analysts also recently issued reports on the stock. Mizuho set a $109.00 price objective on shares of Icon and gave the stock a “hold” rating in a report on Wednesday, January 24th. SunTrust Banks reaffirmed a “buy” rating and set a $133.00 price objective on shares of Icon in a report on Monday, January 22nd. Evercore ISI assumed coverage on shares of Icon in a report on Thursday, January 18th. They set an “outperform” rating and a $126.00 price objective for the company. BidaskClub downgraded shares of Icon from a “sell” rating to a “strong sell” rating in a report on Tuesday, January 16th. Finally, KeyCorp reaffirmed a “buy” rating and set a $130.00 price objective on shares of Icon in a report on Thursday, January 11th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company. Icon presently has a consensus rating of “Buy” and an average price target of $124.55.
Shares of Icon (ICLR) traded down $4.81 on Thursday, hitting $106.93. 462,691 shares of the stock traded hands, compared to its average volume of 291,584. Icon has a 52 week low of $76.46 and a 52 week high of $124.48. The firm has a market cap of $5,790.47, a price-to-earnings ratio of 20.72, a price-to-earnings-growth ratio of 1.51 and a beta of 0.48. The company has a current ratio of 1.90, a quick ratio of 1.90 and a debt-to-equity ratio of 0.31.
A number of institutional investors have recently modified their holdings of the business. WCM Investment Management CA boosted its holdings in Icon by 2.1% in the 3rd quarter. WCM Investment Management CA now owns 4,047,221 shares of the medical research company’s stock valued at $460,897,000 after purchasing an additional 82,115 shares during the period. FMR LLC boosted its holdings in Icon by 38.4% in the 2nd quarter. FMR LLC now owns 2,291,005 shares of the medical research company’s stock valued at $224,037,000 after purchasing an additional 635,950 shares during the period. Wasatch Advisors Inc. boosted its holdings in Icon by 0.7% in the 2nd quarter. Wasatch Advisors Inc. now owns 1,850,244 shares of the medical research company’s stock valued at $180,935,000 after purchasing an additional 13,104 shares during the period. Renaissance Technologies LLC boosted its holdings in Icon by 20.6% in the 2nd quarter. Renaissance Technologies LLC now owns 1,153,160 shares of the medical research company’s stock valued at $112,768,000 after purchasing an additional 197,300 shares during the period. Finally, Boston Partners boosted its holdings in Icon by 0.5% in the 4th quarter. Boston Partners now owns 1,111,725 shares of the medical research company’s stock valued at $124,680,000 after purchasing an additional 5,314 shares during the period. 89.60% of the stock is owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY NOTICE: “Jefferies Group Weighs in on Icon Plc’s Q4 2017 Earnings (NASDAQ:ICLR)” was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international trademark and copyright legislation. The legal version of this piece can be viewed at https://www.dispatchtribunal.com/2018/02/04/q4-2017-earnings-forecast-for-icon-plc-issued-by-jefferies-group-iclr.html.
Icon Company Profile
ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies.
Get a free copy of the Zacks research report on Icon (ICLR)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.